Avadel Pharma (AVDL) Misses Q4 EPS by 4c

Avadel Pharma (NASDAQ: AVDL) reported Q4 EPS of ($0.32), $0.04 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $19.45 million versus the consensus estimate of $18.21 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
• Largo restructures $82.2M in debt, extending maturity to 2030